Guidelines

AAP recommends all infants receive nirsevimab to fight RSV | Image Credit: © Peter Hansen - © Peter Hansen - stock.adobe.com.

The recommendation from the American Academy of Pediatrics (AAP) follows the unanimous recommendation by the CDC advisory group for routine use of nirsevimab in newborns and infants younger than 8 months born into or entering their first RSV season.